Sonpavde GP - Search Results

1

Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.

Ravi P, Ravi A, Riaz IB, Freeman D, Curran C, Mantia C, McGregor BA, Kilbridge KL, Pan CX, Pek M, Choudhury Y, Tan MH, Sonpavde GP. Ravi P, et al. Among authors: sonpavde gp. Oncologist. 2022 May 6;27(5):e406-e409. doi: 10.1093/oncolo/oyac037. Oncologist. 2022. PMID: 35294031 Free PMC article.

2

Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?

Sonpavde G, Bellmunt J. Sonpavde G, et al. Oncologist. 2015 May;20(5):461-3. doi: 10.1634/theoncologist.2015-0077. Epub 2015 Apr 6. Oncologist. 2015. PMID: 25845991 Free PMC article.

3

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M. Bellmunt J, et al. Br J Cancer. 2016 Jun 28;115(1):12-9. doi: 10.1038/bjc.2016.146. Epub 2016 Jun 23. Br J Cancer. 2016. PMID: 27351382 Free PMC article.

4

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK. Pal SK, et al. Eur Urol. 2017 Oct;72(4):557-564. doi: 10.1016/j.eururo.2017.03.046. Epub 2017 Apr 14. Eur Urol. 2017. PMID: 28413127

5

Update of systemic immunotherapy for advanced urothelial carcinoma.

Gartrell BA, He T, Sharma J, Sonpavde G. Gartrell BA, et al. Urol Oncol. 2017 Dec;35(12):678-686. doi: 10.1016/j.urolonc.2017.09.021. Epub 2017 Oct 25. Urol Oncol. 2017. PMID: 29079131 Review.

6

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK. Lalani AA, et al. Among authors: sonpavde gp. Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. Lancet Oncol. 2018. PMID: 29217289 No abstract available.

7

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Jamy O, Sonpavde G. Jamy O, et al. Expert Opin Emerg Drugs. 2017 Dec;22(4):347-355. doi: 10.1080/14728214.2017.1416092. Epub 2017 Dec 19. Expert Opin Emerg Drugs. 2017. PMID: 29226734 Review.

8

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Agarwal N, et al. Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8. Cancer. 2018. PMID: 29517810 Free PMC article.

9

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.

Gourdin T, Sonpavde G. Gourdin T, et al. Asian J Androl. 2018 May-Jun;20(3):230-237. doi: 10.4103/aja.aja_1_18. Asian J Androl. 2018. PMID: 29578115 Free PMC article. Review.

10

Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.

Mossanen M, Chang SL, Kimm S, Sonpavde GP, Kibel AS. Mossanen M, et al. Among authors: sonpavde gp. Urol Clin North Am. 2018 May;45(2):143-154. doi: 10.1016/j.ucl.2017.12.001. Urol Clin North Am. 2018. PMID: 29650131 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters